Top Markets
#1 Akedo Akedo +1.58%
#2 Cash Cat Cash Cat +0.94%
#3 BurnedFi BurnedFi +0.87%
#4 Spiko Amundi Overnight Swap Fund (EUR) Spiko Amundi Overnight Swap Fund (EUR) +0.85%
#5 Euler Euler +0.76%
#6 Axelar Axelar +0.75%
#7 Zebec Network Zebec Network +0.75%
#8 RaveDAO RaveDAO +0.60%
#9 Pirate Chain Pirate Chain +0.51%
#10 SkyAI SkyAI +0.49%
Coin of the day
Akedo Akedo
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Q32 Bio Inc. Q32 Bio Inc.

Q32 Bio Inc.

QTTB
Rang in aandelen #14023
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Aandeelprijs
$14.86
Marktkapitalisatie
$442.29M
Verandering (1 dag)
-1.13%
Verandering (1 jaar)
769.01%
Land
US
Handel Q32 Bio Inc. (QTTB)

Categorie

Healthcare
Omzet van Q32 Bio Inc. (QTTB)
Omzet in Sep 2026 TTM: 0
Volgens de laatste financiële rapporten van Q32 Bio Inc. bedraagt de huidige omzet van het bedrijf (TTM) 0. In 2026 behaalde het bedrijf een omzet van 0 gelijk aan de omzet in het jaar 2026, die 0 bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Q32 Bio Inc. van 2026 tot 2026
Omzet aan het einde van elk jaar
Jaar Omzet Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Omzet van vergelijkbare bedrijven of concurrenten
Bedrijf Omzet Omzetverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH